Pfizer pulls out of Exalenz trial

Pfizer suspended a clinical trial that would use Exalenz's product because of a change in internal priorities

Pfizer Inc. (NYSE: PFZ; LSE: PFE) has notified Exalenz Bioscience Ltd. (TASE:EXEN) that it not carry out the fatty liver and non-alcoholic steatohepatitis (NASH) trial at this time, due to a change in internal priorities at Pfizer. Pfizer was due to use Exalenz's BreathID diagnostic device in this trial.

The announcement will not affect Exalenz's sales, which totaled NIS 1.2 million in the first half of 2008. BreathID analyzes patients' breath to diagnose diseases of the digestive tract. Most sales are for the diagnosis of H. Pylori bacteria, and the company hopes to expand the device's uses in the future.

Exalenz will continue to develop the BreathID to diagnose NASH, and will shortly begin a Phase II clinical trial for this purpose, in addition to the Phase III trial already underway for the diagnosis of liver damage. Pfizer will continue to use BreathID device in its own clinical trials.

Published by Globes [online], Israel business news - www.globes-online.com - on September 11, 2008

© Copyright of Globes Publisher Itonut (1983) Ltd. 2008

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018